REBEKAH SALLES: Open Payments
NPI 1710464136 · BURLEY, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$464 in 16 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $464
Food & beverage: $464
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $219 |
| Novo Nordisk Inc | 2 | $107 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| ABIOMED | 1 | $27 |
| Amgen Inc. | 1 | $19 |
| SCPHARMACEUTICALS INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: Kerendia, Ozempic, ELIQUIS, AMVUTTRA, REPATHA, FUROSCIX, FARXIGA, Rybelsus.
Industry payments across ID — which companies pay providers there.
